-
Mashup Score: 10
TPST-1120 was well tolerated as monotherapy and in combination with nivolumab and the combination showed preliminary evidence of clinical activity in PD-1 inhibitor refractory and immune compromised cancers.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7
The overall value of hepatocellular carcinoma screening is defined by the balance of benefits and harms. Studies have only reported physical harms with none describing financial harms.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0
The phase 3 CheckMate -9DW study of frontline nivolumab plus ipilimumab in hepatocellular cancer met its primary end point of overall survival vs sorafenib or lenvatinib.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 84
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis. The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib. The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 83
Opdivo plus Yervoy demonstrates statistically significant and clinically meaningful improvement in overall survival compared to investigator’s choice of sorafenib or lenvatinib Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy met its primary endpoint of improved overall survival (OS) compared to investigator’s choice of sorafenib or lenvatinib at a pre-specified interim analysis. The dual immunotherapy combination of Opdivo plus Yervoy demonstrated a statistically significant and clinically meaningful improvement in OS compared to investigator’s choice of sorafenib or lenvatinib. The safety profile for the combination of Opdivo plus Yervoy remained consistent with previously reported data and was manageable with established protocols, with no new safety signals
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 43Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma - 1 month(s) ago
In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Current Status of the Liver Imaging Reporting and Data System in Hepatocellular Carcinoma – Gastroenterology & Hepatology - 1 month(s) ago
Victoria Chernyak, MD, MS Professor of Radiology Weill Cornell Medical College Department of Radiology Memorial Sloan Kettering Cancer Center New York, New York Co-Chair of the LI-RADS Steering Committee G & H What are the current uses of the Liver Imaging Reporting and Data System in hepatocellular carcinoma, and what are its main categories? VC There are currently 3 main contexts of use for the Liver Imaging Reporting and Data System (LI-RADS) in hepatocellular carcinoma (HCC). One is surveillance, for
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 26Incidence of Etiology-specific Hepatocellular Carcinoma: Diverging Trends and Significant Heterogeneity by Race and Ethnicity - 2 month(s) ago
The main causes of hepatocellular carcinoma (HCC) include chronic hepatitis C and B viral infections (HCV, HBV), nonalcoholic fatty liver disease (NAFLD), and alcohol-related disease (ALD). Etiology-specific HCC incidence rates and temporal trends on a population-basis are needed to improve HCC control and prevention.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 1Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma – Gastroenterology & Hepatology - 2 month(s) ago
Robin Kate Kelley, MD Professor of Clinical Medicine Division of Hematology/Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California G & H What is the rationale for using durvalumab and tremelimumab in combination for the treatment of hepatocellular carcinoma? RK Durvalumab (Imfinzi, AstraZeneca) and tremelimumab (Imjudo, AstraZeneca) are both immune checkpoint inhibitors, but different ones. Durvalumab is an inhibitor of the programmed
Categories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 5Durvalumab/Bevacizumab/TACE Significantly Extends Survival in HCC - 3 month(s) ago
In an interview with Targeted Oncology, Bruno Sangro, MD, PhD, discussed the potential durvalumab, bevacizumab, and TACE has to set a new standard-of-care among patients with unresectable hepatocellular carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
P1 trial of TPST1120 (PPARα antagonist) https://t.co/TcXVmz0F7w ➡️Metabolic target directly impairs tumor growth & reprograms TME ➡️SD with monotherapy & responses in combo w/ PD1 (2PR w/ prior anti-PD1) ➡️P2 ongoing (TSPT1120+bev/ateo) in #HCC https://t.co/nKy7I3YIbj